Home LiteratureArticle Details
PMID: 17258651 Published · ppublish English Journal Article

Levodopa and the risk of melanoma.

Lancet (London, England) ·Vol. 369 ·No. 9558 ·2007-01-27 ·Pages 257-8

Zanetti R, Rosso S

Abstract

暂无摘要

MeSH Terms
Antiparkinson Agents/adverse effects,therapeutic use Case-Control Studies Humans Levodopa/adverse effects,therapeutic use Melanoma/chemically induced Parkinson Disease/drug therapy,prevention & control Registries Risk Factors Smoking
Chemicals
Antiparkinson Agents Levodopa
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Zanetti Roberto
Piedmont Cancer Registry-CPO, Turin 10123, Italy. roberto.zanetti@cpo.it
Rosso Stefano
Article Info
Journal
Lancet (London, England)
Abbr.
Lancet
ISSN
1474-547X
DOI
10.1016/S0140-6736(07)60125-1
Email
roberto.zanetti@cpo.it
Published
2007-01-27
Pages
257-8
Language
English
Region
England
NLM ID
2985213R
Subset
IM
External Links
PubMed source DOI: 10.1016/S0140-6736(07)60125-1 View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2